ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain Acquires 21,929 Shares

Key Points

• Vivek Jain, CEO of ICU Medical, acquired 21,929 shares of the company's stock for approximately $2.47 million, increasing his total ownership to 130,149 shares.
• ICU Medical reported earnings of $2.10 per share for the last quarter, surpassing estimates and generating revenue of $543.57 million, although revenue fell 8% year-over-year.
• Various institutional investors significantly increased their holdings in ICU Medical, with institutional ownership now at 96.10%.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) CEO Vivek Jain acquired 21,929 shares of ICU Medical stock in a transaction that occurred on Thursday, August 14th. The stock was acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the purchase, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. The trade was a 20.26% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

ICU Medical Stock Performance

ICU Medical stock traded down $2.23 on Thursday, reaching $111.90. 425,806 shares of the stock were exchanged, compared to its average volume of 302,607. The stock has a market cap of $2.76 billion, a PE ratio of -73.62 and a beta of 0.88. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26. The firm has a fifty day moving average price of $128.45 and a two-hundred day moving average price of $138.76.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. During the same quarter in the previous year, the firm posted $1.56 EPS. The business's revenue was down 8.0% compared to the same quarter last year. Sell-side analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ICUI. Quarry LP increased its holdings in shares of ICU Medical by 764.3% during the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 214 shares during the period. Cullen Frost Bankers Inc. bought a new position in shares of ICU Medical during the 2nd quarter worth about $38,000. Russell Investments Group Ltd. increased its holdings in shares of ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 300 shares during the period. GAMMA Investing LLC increased its holdings in shares of ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares during the period. Finally, Sterling Capital Management LLC increased its holdings in shares of ICU Medical by 813.5% during the 4th quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock worth $105,000 after purchasing an additional 602 shares during the period. Institutional investors own 96.10% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Raymond James Financial reduced their price objective on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. KeyCorp cut their target price on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Finally, Wall Street Zen lowered shares of ICU Medical from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $190.33.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.